PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
46.24
+0.99 (2.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for PTC Therapeutics stock have an average target of 51.85, with a low estimate of 30 and a high estimate of 71. The average target predicts an increase of 12.13% from the current stock price of 46.24.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for PTCT stock from 13 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 3 | 3 | 4 | 5 |
| Hold | 6 | 5 | 5 | 4 | 4 | 3 |
| Sell | 2 | 2 | 1 | 1 | 1 | 1 |
| Strong Sell | 3 | 3 | 3 | 3 | 2 | 2 |
| Total | 15 | 15 | 14 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $45 → $67 | Hold → Buy | Upgrades | $45 → $67 | +44.90% | Dec 13, 2024 |
| Citigroup | Citigroup | Strong Sell Maintains $26 → $32 | Strong Sell | Maintains | $26 → $32 | -30.80% | Dec 4, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $32 → $42 | Strong Sell | Maintains | $32 → $42 | -9.17% | Dec 4, 2024 |
| UBS | UBS | Strong Buy Maintains $47 → $71 | Strong Buy | Maintains | $47 → $71 | +53.55% | Dec 3, 2024 |
| Baird | Baird | Buy Maintains $52 → $70 | Buy | Maintains | $52 → $70 | +51.38% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
799.70M
from 937.82M
Decreased by -14.73%
Revenue Next Year
753.33M
from 799.70M
Decreased by -5.80%
EPS This Year
-4.98
from -8.37
EPS Next Year
-3.80
from -4.98
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 854.7M | 926.1M | 1.3B | |||
| Avg | 799.7M | 753.3M | 894.0M | |||
| Low | 751.1M | 559.4M | 459.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -8.9% | 15.8% | 68.9% | |||
| Avg | -14.7% | -5.8% | 18.7% | |||
| Low | -19.9% | -30.1% | -39.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.91 | -0.87 | 0.61 | |||
| Avg | -4.98 | -3.80 | -1.74 | |||
| Low | -6.28 | -6.86 | -5.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.